Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.56 |
| ▸ | SCD | O00767 | 2/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.51 |
| ▸ | CPT1A | P50416 | 5/20 | 0.49 |
| ▸ | CPT2 | P23786 | 4/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968500 | 1.00 | SCD5 (0.56) | SCD5SCDUSP30CPT1ACPT2 | |
| SCHEMBL2897853 | 0.97 | SCD5 (0.59) | SCD5SCDUSP30CPT1ACPT2 | |
| SCHEMBL2897851 | 0.97 | SCD5 (0.59) | SCD5SCDUSP30CPT1ACPT2 | |
| SCHEMBL2890390 | 0.86 | USP30 (0.64) | USP30NPC1TP53HPGDTSHR | |
| SCHEMBL8228401 | 0.86 | USP30 (0.53) | SCD5SCDUSP30CPT1ANPC1 | |
| SCHEMBL8229284 | 0.86 | USP30 (0.53) | SCD5SCDUSP30CPT1ANPC1 | |
| SCHEMBL2890386 | 0.86 | USP30 (0.64) | USP30NPC1TP53HPGDTSHR | |
| SCHEMBL3963501 | 0.86 | SCD5 (0.60) | SCD5SCDUSP30CPT1ACPT2 | |
| SCHEMBL3963506 | 0.86 | SCD5 (0.60) | SCD5SCDUSP30CPT1ACPT2 | |
| SCHEMBL2899277 | 0.84 | USP30 (0.57) | SCD5USP30NPSR1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | SCD5 378/4885SCD 1757/4885USP30 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.